What is the "Vyleesi (HSDD in women)" protocol for PT-141?

1.75 mg · As needed, 45 min before · Episodic; max 8/month

Dosing

PT-141 (Bremelanotide / Vyleesi) - dosing protocol

PT-141 (FDA-approved Vyleesi) is dosed at 1.75 mg under the skin (s.c. injection) as needed, 45 minutes before anticipated effect. Not more than 8 doses per month. Acts centrally on the hypothalamus (MC4R) — unlike peripheral vasodilators (vessel dilators).

Route

Subcutaneous (s.c.) — abdomen or thigh

Dose

1.0-1.75 mg as needed

Half-life

~2.7 hours

Storage

-20°C lyophilized; reconstituted — 30 days at 2-8°C

Dosing regimens

Standard regimens from the literature. The choice depends on what you're trying to achieve.

Protocol

Vyleesi (HSDD in women)

Dose: 1.75 mg
Frequency: As needed, 45 min before
Duration: Episodic; max 8/month

Side effects

Nausea is the most common effect (40% in clinical trials) — especially the first 1-2 doses, with tolerance building afterward. Transient blood pressure elevation is documented in the Vyleesi approval.

See full side-effect list

Encyclopedia

Full scientific profile for PT-141

Calculator

What does this protocol cost per day?

Last reviewed: 6 May 2026by PeptidLabs Editorial